Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.
Location: United States, New Jersey, Hampton
Employees: 51-200
Founded date: 1983
Investors 2
| Date | Name | Website |
| - | Albion Cap... | albion.cap... |
| - | Ignite 500 | ignite500.... |
Mentions in press and media 17
| Date | Title | Description |
| 01.03.2025 | Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 | - Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of CIndU patients report... |
| 08.08.2024 | Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Phase 3 CSU studies initiated July 2024 Positive topline Phase 2 CIndU 12 week data reported July 2024 supporting Phase 3 advancement 52 week Phase 2 CSU data and full 12 week Phase 2 CIndU data to be reported 2H 2024 Enrollment continues i... |
| 08.03.2024 | Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference | - |
| 05.03.2024 | Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference | - |
| 05.03.2024 | Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares | - |
| 01.03.2024 | Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock | HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a publ... |
| 29.02.2024 | Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock | - |
| 06.11.2023 | XBI biotech index rises, giving investors a shred of hope | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Monday. So, we’ve got a welcome bump in the XBI, see that European regulatory conditions are prompting Ozempic... |
| 14.07.2021 | Celldex Therapeutics : Announces Pricing of Upsized $250 Million Public Offering of Common Stock | HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offer... |
| 30.03.2021 | Biotechs Working on Potential Preventive Measures and Cancer Treatments | FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, March 30, 2021 /PRNewswire/ -- Cancer research and development are a major part of the biotechnology industry, and there is always room for improvement and growth. Recent... |
Show more